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Cytokine elevation in severe and critical COVID-19: a rapid
systematic review, meta-analysis, and comparison with
other inflammatory syndromes
Daniel E Leisman*, Lukas Ronner*, Rachel Pinotti, Matthew D Taylor, Pratik Sinha, Carolyn S Calfee, Alexandre V Hirayama, Fiore Mastroiani,
Cameron J Turtle, Michael O Harhay, Matthieu Legrand, Clifford S Deutschman

The description of a so-called cytokine storm in patients with COVID-19 has prompted consideration of anti-cytokine
therapies, particularly interleukin-6 antagonists. However, direct systematic comparisons of COVID-19 with other critical
illnesses associated with elevated cytokine concentrations have not been reported. In this Rapid Review, we report the
results of a systematic review and meta-analysis of COVID-19 studies published or posted as preprints between Nov 1, 2019,
and April 14, 2020, in which interleukin-6 concentrations in patients with severe or critical disease were recorded.
25 COVID-19 studies (n=1245 patients) were ultimately included. Comparator groups included four trials each in sepsis
(n=5320), cytokine release syndrome (n=72), and acute respiratory distress syndrome unrelated to COVID-19 (n=2767).
In patients with severe or critical COVID-19, the pooled mean serum interleukin-6 concentration was 36·7 pg/mL (95% CI
21·6–62·3 pg/mL; I²=57·7%). Mean interleukin-6 concentrations were nearly 100 times higher in patients with cytokine
release syndrome (3110·5 pg/mL, 632·3–15 302·9 pg/mL; p<0·0001), 27 times higher in patients with sepsis (983·6 pg/mL,
550·1–1758·4 pg/mL; p<0·0001), and 12 times higher in patients with acute respiratory distress syndrome unrelated to
COVID-19 (460 pg/mL, 216·3–978·7 pg/mL; p<0·0001). Our findings question the role of a cytokine storm in
COVID-19-induced organ dysfunction. Many questions remain about the immune features of COVID-19 and the potential
role of anti-cytokine and immune-modulating treatments in patients with the disease.

Introduction
COVID-19 is a new and poorly understood disease, so
much of our current understanding of organ dysfunction
in severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) infection is extrapolated from other disor
ders with similar clinical features. Several studies have
reported elevated serum concentrations of inflam
matory cytokines, including interleukin (IL)-6, in severe
COVID-19.1,2 These observations have spurred com
parisons with other syndromes of critical illness that are
associated with elevated cytokines. Frequently invoked
examples are acute respiratory distress syndrome
(ARDS) and sepsis.3 Cytokine release syndrome in the
setting of chimeric antigen receptor (CAR) T-cell therapy
is another comparator of particular interest because it
is a US Food and Drug Administration-approved
indication for the drug tocilizumab.4 Tocilizumab is
a humanised monoclonal antibody against the
IL-6 receptor.5 On the basis of these comparisons, trials
of anti-cytokine medications are ongoing in patients
with COVID-19. Administration of these medications,
inclu
ding IL-6 antagonists, has become widespread
while awaiting trial results.1 How
ever, a systematic
comparison of the inflammatory milieu in COVID-19associated critical illness and these other disorders has
not been done. Such a comparison might reveal
important similarities and differences between these
various syndromes and inform the successful appli
cation of immune-modulating therapy in COVID-19.
In this Rapid Review, we describe a rapid systematic
review and meta-analysis of inflammatory cytokine and
related biomarker concentrations in the COVID-19
literature. We compare the findings in patients with

COVID-19 with those reported in landmark studies of
patients with ARDS unrelated to COVID-19, sepsis, and
CAR T cell-induced cytokine release syndrome. We discuss
the implications for understanding of the pathobiology of
each of these four syndromes, highlighting current
uncertainties, and for future research and clinical practice.

Key messages
• Inflammatory cytokine elevations in patients with severe
and critical COVID-19, including elevations of interleukin-6,
are profoundly lower than those reported in patients with
acute respiratory distress syndrome (ARDS) unrelated to
COVID-19, sepsis, and chimeric antigen receptor (CAR)
T cell-induced cytokine release syndrome
• In contrast, several non-cytokine biomarkers, including
D-dimer, C-reactive protein, and ferritin, are elevated to
a similar or greater extent in patients with COVID-19
than in patients with these comparison disorders
• As in other syndromes of critical illness, the role
of inflammatory cytokine elevations in the pathobiology
of COVID-19 remains unclear
• The systemic inflammatory profile of COVID-19 is
distinct from that of non-COVID-19 ARDS, sepsis, and
CAR T cell-induced cytokine release syndrome; applying
the descriptor cytokine storm to COVID-19 might be
particularly problematic
• Alternative models of organ dysfunction in COVID-19, such
as endovasculitis, direct viral injury and lymphodepletion,
or viral-induced immunosuppression, might be worth
considering
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Methods

Study outcomes

Aims and overview
The aims of this Rapid Review were to synthesise and
describe the reported pattern of inflammatory cytokines in
COVID-19-induced respiratory failure and to compare this
profile with those of other acute inflammatory syndromes.
We did a rapid systematic review of the literature to
describe inflammatory cytokine concentrations in severe
and critical COVID-19. The primary response variable was
plasma or serum IL-6. Addi
tionally, concentrations of
other cytokines, acute-phase reactants, and related bio
markers were recorded. Results were then compared with
control populations identified from landmark trials of
ARDS, sepsis, and cytokine release syndrome. A sub
analysis distinguished results in severe versus critical
COVID-19.

Search strategy and selection criteria

See Online for appendix 1
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For COVID-19, we included original research studies that
reported IL-6 concentrations for hospitalised patients
with either severe or critical laboratory-con
firmed
COVID-19. Severe COVID-19 was identified by criteria of
either WHO6 or the National Health Commission of
China7 (appendix 1 p 8). We classified patients with critical
COVID-19 as those who met the criteria of either WHO6
or the National Health Commission of China7 for
COVID-19-induced ARDS (which align with the
Berlin Definition of ARDS8), or who were admitted to an
intensive care unit (ICU) and received invasive
mechanical ventilation if severity was not other
wise
specified. Case series including only deceased patients
were also treated as having critical COVID-19. We excluded
studies that had fewer than 20 participants, were not
written in English, or for which measures of central
tendency and distri
bution could not be obtained.
A medical librarian (RP) designed and executed a compre
hensive search strategy (appendix 1 p 2) of articles
published between Nov 1, 2019, and April 14, 2020, in the
Embase and MEDLINE databases. Additional searching
was done in the medRxiv repository for relevant preprints.
Titles and abstracts of results from all sources were
screened by one reviewer (LR or DEL). The full text of
relevant articles was then reviewed to identify studies for
analysis.
For the comparator disorders, data were obtained
from pre-specified landmark trials. For ARDS, we used
data reported from the SAILS trial and from the pooled
analysis of the ALVEOLI, ARMA, and FACCT trials.9,10
For sepsis, data were obtained from the ACCESS,
PROWESS, ProCESS, and GenIMS studies.11 For
cytokine release syndrome, we obtained data from
studies of a spectrum of haematological malignancies
that were treated with CAR T-cell therapy.12–15 We
restricted the data to patients with cytokine release
syndrome of grade 3 or higher, which generally involves
organ dysfunction that prompts the administration of
tocilizumab (grading criteria are given in appendix 1 p 9).

The primary response variable was plasma or serum IL-6
concentration. Additional response variables of interest
included tumour necrosis factor-α (TNFα), IL-8, IL-1β,
IL-10, IL-2, IL-4, soluble IL-2 receptor (sIL-2R), inter
feron-γ (IFNγ), C-reactive protein (CRP), ferritin, D-dimer,
procalcitonin, lactate dehydrogenase, erythrocyte sed
imentation rate, albumin, total bilirubin, fibrinogen,
lymphocyte count, lymphocyte percentage, and platelet
count.

Accuracy of published data and inclusion of preprints
We adhered to a rapid (rather than traditional systematic)
review methodology.16 We chose this approach in an
attempt to balance systematic data collection with the
need for rapid synthesis and reporting in the context of
the pandemic. Given the rapid pace at which research
related to COVID-19 is being disseminated, we were
concerned about a relatively high frequency of corrections
and errata. Accordingly, once all eligible studies were
identified, one author (LR) reviewed each paper on the
publisher’s website to check whether any corrections had
been issued.
The need for rapid dissemination of COVID-19
research had spurred many authors to post their studies
as preprints, particularly on the website of medRxiv.
We included these non-peer-reviewed preprints to
capture a larger sample of observations during the brief
time since COVID-19 has emerged. Given the descriptive
nature of our research question (as opposed to a causal
treatment effect), we reasoned that the risk of bias due to
an absence of peer review was less concerning than
potential biases due to the inclusion of only early
manuscripts that had had time to navigate peer review.
This study did not operate in a prediction or causal
inference framework, so we did not assess patient out
comes or their association with cytokine concentrations,
to respect the limitations of descriptive modelling and
inference; nor did we undertake a formal risk-of-bias
assessment.17,18

Data abstraction
One of two reviewers (DEL or LR) abstracted data from
all studies that met inclusion criteria using a stan
dardised data collection tool. It has been suggested that
cytokine elevation is a late finding in COVID-19.4 To
address this concern, we abstracted the peak IL-6 value
for studies that reported multiple IL-6 concentrations.
All included studies reported a measure of central
tendency (mean or median) and dispersion (SD,
standard error, IQR, or range) for IL-6 concentrations.
For studies that did not report these statistics (eg, IL-6
reported as frequencies of categorical concentrations, or
in a figure that was difficult to interpret), or that did not
report them in the specific population of interest
(eg, in an overall study population that included
non-severe COVID-19), the data were requested from

www.thelancet.com/respiratory Published online October 16, 2020 https://doi.org/10.1016/S2213-2600(20)30404-5

Rapid Review

the corresponding authors. All of these authors were
con
tacted at least three times over a 3-week period.
If the corresponding author did not provide the data and
the statistics could not be identified from the reporting
format, the study was excluded. Measurement units
were standardised across studies for comparison (more
detail is provided in appendix 1 p 5).

402 references imported for screening

67 duplicates removed

335 studies screened by title and abstract

Data analysis
Mean and SD were used when reported in selected
studies. When median and IQR or range were reported,
we adhered to Cochrane recommendations, estimating
the mean using the method described by Wan and
colleagues19 and the SD using the Cochrane handbook
method.20 Because we expected many markers to display
a beta distribution, we evaluated each response variable
graphically before analysis and applied a log trans
formation if normality assumptions were violated.
We included the analysis of the untransformed data as
sensitivity analyses. Additionally, after data collection, we
found that the central tendency was positively correlated
with variance (ie, the homoscedasticity assumption was
violated) for many biomarkers, including IL-6. Because
the common practice of inverse-variance weighting
would bias the estimates downwards in this situation,21
we instead weighted studies by the square root of the
sample size in the primary analysis. However, we also
did standard inverse-variance weighting as sensitivity
analyses.
After computing study weights, pooled means were
calculated from a generalised linear model with disorder
as a class variable with the levels COVID-19, cytokine
release syndrome, hypoinflammatory ARDS, hyperinflam
matory ARDS, and sepsis, by estimating the least-squares
means at each level. We constructed 95% CI and p values
for the difference between COVID-19 and each of the other
disorders using Dunnett’s correction for multiple com
parisons. To facilitate interpretation for variables that had
been log-transformed, we back-transformed the results for
reporting purposes. We calculated I² statistics to assess
between-study heterogeneity within disorders.
For the secondary analyses, separate levels for severe and
critical COVID-19 were included in the disorder variable.
Unlike critical COVID-19, severe COVID-19 might have
included a less severely ill population than that of
non-COVID-19 ARDS. To address whether lower severity
explained discrepancies in cytokine concentrations, we
selected critical COVID-19 as the reference level for
statistical hypothesis testing. As an additional sensitivity
analysis, IL-6 concentrations were calculated among only
COVID-19 studies that reported peak IL-6. Further details
and rationale of the quantitative strategy are provided in
appendix 1 (pp 6–7). The analyses were done in SAS
University Edition. Figures were produced using GraphPad
Prism 8. We provide the complete dataset used in these
analyses in appendix 2. The study is registered with
PROSPERO, CRD42020180350.

271 deemed irrelevant

64 full-text studies assessed for eligibility

39 studies excluded
13 patients with severe or critical COVID-19 not
included or identified
12 interleukin-6 or TNFα concentration not reported
3 mean (SD) or median (IQR) not reported in tables
or graphs
3 mean (SD) or median (IQR) presented graphically
but difficult to estimate; authors contacted but
failed to provide clarification
3 fewer than 20 patients
2 duplicates
2 not in English
1 ex vivo laboratory study using human tissue

25 COVID-19 studies included

4 ARDS, 4 sepsis, and 4 CAR T cell-induced
CRS studies selected (large, prospectively
collected datasets with robust biomarker
data)

37 studies included in meta-analysis

Figure 1: Selection of studies
ARDS=acute respiratory distress syndrome. CAR T cell-induced CRS=chimeric antigen receptor T cell-induced
cytokine release syndrome.

Results

Search results
The COVID-19 search strategy returned 335 search
results (figure 1). Abstract screening identified 64 studies
for full-text review; 28 of these studies met the inclusion
criteria. Six of these 28 studies did not report results in a
format that easily facilitated data abstraction. All of these
six reports indicated that data were available on request.
Of the six corresponding authors whom we contacted,
two provided data, one declined citing hospital datasharing rules, and three did not answer after multiple
contact attempts (appendix 1 p 10). Subsequently, we
were able to estimate IL-6 concentrations from a figure
in one of the four studies that did not provide requested
data. Ultimately, 25 COVID-19 studies reflecting
1245 patients were included for analysis.2,22–45 Of these,
15 studies (n=650 patients) either included only patients
with severe COVID-19 or allowed data abstraction speci
fically within the subgroup of patients with severe
disease, whereas ten studies (n=367 patients) included
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only patients with critical COVID-19 or allowed data
abstraction specifically within the subgroup of patients
with critical illness. COVID-19 study details are provided
in appendix 1 (p 11).
Non-COVID-19 studies are summarised in appendix 1
(p 12). The four ARDS trials included 2767 patients.9,10 Of
these, 1899 had the hypoinflammatory phenotype and
868 had the hyper
inflammatory phenotype. The four
sepsis cohorts included 5320 patients.11 The four studies of
cytokine release syndrome were smaller, with 72 patients
included in the final analysis.12–15

IL-6 in COVID-19 versus other disorders
In the primary analysis, the estimated pooled mean for IL-6
concentrations in patients with COVID-19 was 36·7 pg/mL
(95% CI 21·6–62·3 pg/mL; figure 2, appendix 1 p 13). In
contrast, the mean IL-6 serum concentration was
3110·5 pg/mL (632·3–15 302·9 pg/mL) in patients with
CAR T cell-induced cytokine release syndrome, nearly
100 times higher than in patients with COVID-19
(difference 3074 pg/mL, 95% CI 325–26 735 pg/mL;
p<0·0001). Similarly, the pooled mean IL-6 concentration
was 1558·2 pg/mL (525·8–4617·6 pg/mL) in patients with
hyper
inflammatory ARDS (difference 1521·5 pg/mL,
324·7–26 735·0 pg/mL; p<0·0001) and 983·6 pg/mL
(550·1–1758·4 pg/mL) in patients with sepsis (difference
947 pg/mL, 324–2648 pg/mL; p<0·0001). Even in
patients with hypoinflammatory ARDS, the mean IL-6
concentration was 198·6 pg/mL (80·6–489·3 pg/mL),
5 times higher than the concentration in patients with
COVID-19 (difference 162 pg/mL, 16–717 pg/mL;
p=0·0085). Patients with ARDS unrelated to COVID-19
had significantly higher IL-6 concentrations than did
4

patients with COVID-19 when analysed as a single
disor
der (mean 460·1 pg/mL, 216·3–978·7 pg/mL;
difference 423·4 pg/mL, 106·9–1438·1 pg/mL; p<0·0001;
appendix 1 p 14). In the sensitivity analysis using inversevariance weighting, estimated means were lower than in
the primary analysis for all groups, but between-group
differences were similar to the primary analysis
(appendix 1 p 13). In the sensitivity analyses in which IL-6
concentrations were not transformed, all mean estimates
were higher and between-group differences were even
larger than in the primary analysis, but the model fit
appeared to be substantially worse (appendix 1 p 13).
IL-6 concentrations in patients with COVID-19 showed
moderate heterogeneity (I²=57·7%), with a range of
6·5–357·2 pg/mL, and 80·0% of the COVID-19 studies
reported a mean IL-6 concentration lower than 100 pg/mL.
Heterogeneity was lower for hyperinflammatory (I²=0%)
and hypoinflammatory ARDS (I²=37·6%), but higher for
cytokine release syndrome (I²=77·0%) and sepsis
(I²=89·3%).

Additional inflammatory cytokines
Most other cytokines were comparatively low in
COVID-19 (figure 3; appendix 1 p 16). For example, the
mean IL-8 concentration (neutrophil chemotactic factor)
was 22 pg/mL (95% CI 5–108 pg/mL) in patients with
COVID-19, compared with 228 pg/mL in patients with
sepsis (difference 206 pg/mL, 95% CI 15–1371 pg/mL;
p=0·021) and 196 pg/mL in patients with hyper
inflammatory ARDS (difference 174 pg/mL, 5–1436 pg/mL;
p=0·038). The mean IL-8 concentration in patients with
cytokine release syndrome was 575 pg/mL; the difference
between mean IL-8 concentration in patients with
cytokine release syndrome versus COVID-19 was
not statistically significant in the setting of a wide
CI (difference 553 pg/mL, –47 to 47 502 pg/mL; p=0·11).
However, the estimate for IL-8 concentration in patients
with hypoinflammatory ARDS was 32 pg/mL, similar to
that for COVID-19. TNFα concentrations were available
for the four studies examining sepsis (n=5320) and one
study examining cytokine release syndrome (n=16), and
for ten COVID-19 studies (n=607 patients). Compared
with a mean TNFα concentration of 5·0 pg/mL
(2·3–10·7 pg/mL) in patients with COVID-19, mean con
centration was 34·6 pg/mL (20·0–59·9 pg/mL) in
patients with sepsis and 52·2 pg/mL (2·0–1390 pg/mL)
in patients with cytokine release syndrome. All but
one (92%) COVID-19 study had a mean TNFα concen
tration lower than 10 pg/mL. IFNγ concentrations were
reported in seven COVID-19 studies (n=165) and sIL-2R
concentrations were reported in three COVID-19 studies
(n=335), and for two studies examining cytokine release
syndrome (n=24). IFNγ concentration was not elevated in
patients with COVID-19, with an average of 10·8 pg/mL,
but was highly elevated in patients with cytokine
release syndrome, averaging 3722·1 pg/mL (difference
3711 pg/mL, 624–21 838 pg/mL; p<0·0001). Mean sIL-2R
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was elevated in patients with COVID-19, but much less
so than in patients with cytokine release syndrome
(506 pg/mL vs 12 396 pg/mL; difference 11 890 pg/mL,

299–190 957 pg/mL; p=0·032). IL-2 and IL-4 concen
trations were not available in any study of the comparison
disorders, but IL-2 concentration was repor
ted in

B
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Liu et al (2020)39
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Figure 2: Interleukin-6 concentrations in patients with COVID-19 versus comparison disorders
(A) Pooled estimate for each disorder. Markers indicate point estimates and error bars indicate 95% CIs. (B) For individual studies, markers indicate study means and
error bars indicate standard deviations. Markers are sized proportionately to the log weight of the study in the analysis. Pooled estimates are represented by the solid
bars. The black marking in the centre of the bars indicates the point estimate for the disease. The width of the box is scaled according to the pooled number of
participants, whereas the width of the bar indicates the 95% CI. ARDS=acute respiratory distress syndrome. CAR=chimeric antigen receptor. CRS=cytokine release
syndrome.
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Figure 3: Additional cytokines and biomarkers in patients with COVID-19 versus comparison disorders
The figure shows pooled mean estimates for secondary analyses of inflammatory cytokines and markers. Markers indicate point estimates and error bars indicate 95% CIs. ARDS=acute respiratory
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nine COVID-19 studies and IL-4 concentration in
ten COVID-19 studies. All of these COVID-19 studies rep
orted these cytokines to be within normal physiological
range.

Other inflammatory and host-response markers
Acute-phase reactants were substantially elevated in
patients with COVID-19 (figure 3; appendix 1 p 16).
6

CRP concentrations were comparable in patients with
COVID-19 and patients with sepsis, and higher in
patients with cytokine release syndrome. D-dimer
concentrations were available for COVID-19 and sepsis
studies; these studies indicated that patients with
COVID-19 had substantially higher D-dimer elevations
than did patients with sepsis. Mean ferritin and lactate
dehydrogenase concentrations were markedly higher in
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patients with cytokine release syndrome than in patients
with COVID-19, but none
theless highly ele
vated in
patients with COVID-19. In contrast, procal
citonin
concentrations were not elevated in patients with
COVID-19 but were raised in sepsis. Absolute and
relative lymphopenia were common in patients with
COVID-19, but data were not available in the comparison
groups. We report results for additional markers in
appendix 1 (p 16).

Severe versus critical COVID-19 versus other disorders
The pooled mean IL-6 concentration in patients with
critical COVID-19 was 55·3 pg/mL, and was not statistically
greater than in patients with severe COVID-19 (mean
37·3 pg/mL; p=0·94; figure 2). This pooled mean IL-6
concentration in patients with critical COVID-19 was again
significantly lower than in patients with all other
non-COVID-19 comparator disorders. Sensitivity analysis
using inverse-variance weighting showed the same
result (appendix 1 p 17). Most of the within-COVID-19
heterogeneity in the primary analysis appeared to be
driven by the group with critical COVID-19, in which the
I² was 55·7%, compared with 1·1% in the group with
severe COVID-19. The mean IL-6 concentration among
studies of patients with critical COVID-19 ranged from
22·3 pg/mL to 136·8 pg/mL, with six of ten studies
reporting mean IL-6 concentration lower than
100·0 pg/mL.
Other cytokine measures in the subgroup of patients
with critical COVID-19 were similar to those observed in
the primary analysis. In contrast, abnormalities of noncytokine biomarkers appeared to be exaggerated in the
group with critical versus severe COVID-19 (figure 3;
appendix 1 p 18).

Peak IL-6 in COVID-19 versus other disorders
The time of IL-6 concentration measurement for all
studies is shown in appendix 1 (p 19). Among COVID-19
studies reporting peak IL-6 concen
tration (six studies,
n=245 patients), mean IL-6 concentration was 61·3 pg/mL
in patients with COVID-19, significantly lower than in
patients with sepsis, cytokine release syndrome, and
hyperinflammatory ARDS (appendix 1 p 20). Results were
similar when comparing peak IL-6 concentrations in
patients with critical COVID-19 alone (mean 78·1 pg/mL)
with those for the other disorders.

Discussion
In this Rapid Review of 25 studies reflecting 1245 patients
with severe and critical COVID-19, plasma or serum IL-6
concentrations were at least an order of magnitude less
than those reported in studies of patients with CAR
T cell-induced cytokine release syndrome, sepsis, and
non-COVID-19 ARDS. This finding was consistent
across several sensitivity analyses. Most other cytokine
concentrations also showed mild elevation in patients
with COVID-19 as compared with the other disorders. In

contrast, non-specific inflam
matory markers appeared
to be relatively comparable between COVID-19 and
non-COVID-19 illnesses. These results build on a
preliminary analysis in patients with COVID-19 versus
patients with ARDS unrelated to COVID-19.46

Pathobiology of COVID-19
Our results suggest that the descriptor cytokine storm
does not appropriately describe the milieu in COVID-19induced organ dysfunction. Autopsy reports consistently
note widespread dissemination of SARS-CoV-2 through
out diverse tissues.47 Lymphopenia is common, as we
report here, and prognostic, as others have reported.1,48
T lymphocytes are directly susceptible to SARS-CoV-2
infection,49 and are depleted in clinical COVID-19.22,28
In this context, it is worth considering that the less pro
nounced cytokine elevations in COVID-19 could reflect
a regulated, or even inadequate, inflammatory response to
overwhelming viral infection. A predominantly hypo
immune state with subsequent (directly) virus-mediated
tissue damage and dysregulated inflammation is con
sistent with both the apparent clinical and pathological
abnormalities in COVID-19 and the high concentrations of
circulating acute-phase reactants reported here (figure 4).3,50
In contrast to cytokine concentrations, similar or
greater elevations of several acute-phase reactants and
other biomarkers were found in patients with COVID-19.
D-dimer concentrations were 5 times higher in patients
with critical COVID-19 than in patients with sepsis,
suggesting that the reported associations between
D-dimer and severity in COVID-19 are a consistent and
distinguishing signal. Although prediction inference is
outside the scope of the present study, the ability of
D-dimer and procalcitonin to discriminate COVID-19
from other infectious causes of respiratory distress might
warrant further exploration.
Importantly, although the mortality benefit from dexa
methasone treatment reported in patients with COVID-19
informs clinical practice,51 it is difficult to causally
attribute this benefit to IL-6 suppression. Of the myriad
effects of glucocorticoids relevant to critical illness
(eg, inotropy, vasoconstriction in the more than 60% of
critically ill patients with COVID-19 who require
vasopressor support1), perhaps the most relevant is the
ability of corticosteroids to suppress the late-onset fibrosis
that leads to irreversible lung damage in ARDS.52 Notably,
the large effect in the RECOVERY trial of dexamethasone
was driven entirely by patients who were randomised
more than 7 days after symptom onset.51

Pathobiology of ARDS
Because it arises from a range of precipitating causes,
ARDS is associated with numerous pathobiological
processes. Central to its pathogenesis is an acute inflam
matory insult leading to pulmonary epithelial and
endothelial injury. The extent to which these injuries are
observed can depend on the site of insult. For example,
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Figure 4: Mechanistic comparison of inflammatory processes in patients with COVID-19 versus ARDS, sepsis, and CAR T cell-induced CRS
ARDS=acute respiratory distress syndrome. CAR T cell-induced CRS=chimeric antigen receptor T cell-induced cytokine release syndrome. CRP=C-reactive protein. DAMPs=damage-associated molecular
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circulating markers of epithelial injury are more elevated
in patients with direct causes (eg, pneumonia, aspiration)
than in those with indirect causes (eg, pancreatitis) of
ARDS. Conversely, indirect causes are associated with
higher concentrations of endothelial injury markers.53
Distinct hypoinflammatory and hyperinflammatory
phenotypes of ARDS, which differ on the basis of
systemic inflam
matory profiles, have been robustly
identified. The hyperinflammatory phenotype is
associated with increased concentrations of IL-6, IL-8,
and soluble TNF receptor 1, but lower concentrations of
protein C.
In patients with COVID-19, the relative contributions
of endothelial and epithelial injury remain unknown.
Given that viral pneumonitis is a direct cause of lung
injury, it might be anticipated that epithelial injury would
be predominant. Numerous post-mortem studies in
patients with COVID-19 ubiquitously identified diffuse
alveolar damage in patients with severe disease.54,55 Yet,
these studies also describe severe endothelial damage
and coag
ulopathic features in the pulmonary micro
vasculature.54,55 These studies require cautious inter
pretation because they are subject to selection bias and
the sample sizes are small. In an exploratory prospective
8

study, the hyperinflammatory phenotype of ARDS was
observed in 11–20% of patients with COVID-19 versus
35% of patients with non-COVID-19 ARDS.56 This
finding substantiates the results of this meta-analysis,
suggesting that circulating inflammatory responses are
generally lower in patients with COVID-19 than in
patients with hyperinflammatory ARDS.

Pathobiology of sepsis
Sepsis is defined as life-threatening organ dysfunction
caused by a dysregulated host response to infection.57 The
syndrome has diverse infectious causes and host
substrates, which probably underlie the great hetero
geneity in its manifestations. The precise biological
events that precipitate transition from regulated to dys
regulated host response remain unknown. The sine qua
non of sepsis is organ dysfunction, often remote from the
infectious source. Abnormalities include vasodilatory
shock, ARDS, coagulopathy, and renal, hepatic, micro
circulatory, and endocrine dysfunction. Immune dys
function is another hallmark of sepsis, but conceptualising
this dysfunction as hyperinflammation is probably too
simplistic. While inflammatory cytokine concentrations
are often exceptionally high, sepsis is also associated with
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immunosuppression marked by T cell exhaustion, neu
trophil hyporesponsiveness to cytokine stimulation, and
impaired innate cell phagocytosis and pathogen killing.58
Elevated cytokines coupled with impaired immune
effector function is a pattern consis
tent with the
peripheral resistance observed in multiple endocrine axes
in sepsis. Therefore, whether inflammatory cytokine
elevations in sepsis reflect a driver, a marker, or even an
adaptive response to disease remains unknown.
Unanswered questions about the mechanistic role of
cytokine elevations are shared between sepsis and
COVID-19. However, despite much lower systemic
cytokine concentrations, ex vivo stimulated blood mono
nuclear cells from patients with COVID-19 produced half
as much TNFα and IFNγ as did cells from patients with
sepsis and patients with critical illness without any
infection.59 Therefore, immunosuppression might be
even more pronounced in patients with COVID-19 than
the paradoxical suppression frequently observed in
sepsis.58,59 Innate clearance capacity of microorganisms
has not been investigated in patients with severe
COVID-19 yet, and is probably a key question for future
studies given the high risk of secondary infection among
patients in ICUs.

Pathobiology of CAR T cell-induced cytokine release
syndrome
Unlike sepsis and ARDS, CAR T cell-induced cytokine
release syndrome has a well defined pathophysiology.
After infusion, CAR T cells encounter cognate antigen,
leading to activation, proliferation, and lysis of target cells
with inflammatory cytokine release.60–62 CAR T-cell
infusion is associated with fever, hypotension, coagulo
pathy and, in severe cases, multiorgan dysfunction that
might include reversible neurotoxicity. In most patients,
cytokine release syndrome develops shortly after infusion
and resolves in the ensuing week with supportive care
alone or in association with tocilizumab or corticosteroid
treatment.60,62–64 However, severe or prolonged cytokine
release syndrome is assoc
iated with extraordinarily
high serum concentrations of inflammatory cytokines,
including IFNγ, IL-6, IL-10, IL-15, and TNF receptor p55,
and chemokines, such as IL-8.60 Prompt resolution of
fever and, often, hypotension after tocilizumab admini
stration suggests that IL-6 contributes to the pathobiology
of CAR T cell-induced cytokine release syndrome,
although randomised evidence is lacking. Laboratory
studies suggest that monocytes and macrophages are a
major source of IL-6 after CAR T-cell therapy. Release of
IL-1 appears to precede that of IL-6, so targeting of IL-1
signalling might mitigate or prevent cytokine release
syndrome.65,66 Ferritin concentrations rise substantially in
patients with severe cytokine release syndrome, which
might signify macrophage activation.
Elevations in ferritin, CRP, and cytokines such as IL-6
in patients with COVID-19 have spurred comparisons
to CAR T cell-associated cytokine release syndrome.

However, the comparatively low IL-6 concentrations and
absence of substantial IFNγ elevations in patients with
COVID-19 limit the analogy to cytokine release
syndrome. Conversely, low IL-6 and high ferritin
concentrations in patients with COVID-19 are in fact
consistent with haemophagocytic lymphohistiocytosis
or a macro
phage activation syndrome.67 However,
analogies are again limited by the absence of substantial
IFNγ elevations in patients with COVID-19. Some
researchers have proposed immunosubphenotypes of
COVID-19, whereby some patients show so-called
immunoparalysis and others a pattern similar to that
of macrophage activation syndrome.68 Under this
paradigm, the pheno
type similar to macrophage
activation syndrome represent a minority (<15%) of
patients.68 Insufficient high-quality data on cyto
kine
patterns in haemophagocytic lympho
histio
cytosis or
macrophage activation syndrome in a format conducive
to analysis precluded the inclusion of these diagnoses in
our analyses.

Implications for research and clinical practice
The results of our systematic review and meta-analysis
raise concerns about the widespread off-label use of
cytokine blockade in the treatment of COVID-19 before
the results of randomised trials are available. Cytokine
blockade has not been effective in patients with sepsis
and ARDS, in whom inflammatory cytokine concen
trations are far more elevated. IL-6 elevation might have
a role in endothelial activation and precipitation of a
pulmonary immune-mediated thrombosis, so ongoing
trials might ultimately show that anti-cytokine treatment
is beneficial in some patients with COVID-19.69
However, unencumbered use of these agents in the
absence of randomised evidence seems premature. We
note that the current Infectious Disease Society of
America guidelines recommend against the use of
tocilizumab in patients with COVID-19-associated
ARDS outside the context of a clinical trial,70 but IL-6
and IL-1 antagonists have nevertheless been widely
administered—to nearly 20% of patients with COVID-19
in ICUs in some studies.1
The intense focus on cytokine blockade has attracted
substantial investment. Such focus might have incurred
the opportunity cost of discouraging clinical exploration of
other hypotheses, such as immunosupportive therapy.
There are at least 20 trials of various IL-6 antagonists for
COVID-19 registered with ClinicalTrials.gov. In contrast,
there is a single unique trial for recombinant IL-7, which
has been effective in previous randomised trials of severe
viraemic illnesses. There are just four trials of interferons
despite evidence that inhibition of IFN-1 signalling is an
intrinsic mechanism of immune evasion by SARS-CoV-2.
A single trial of all CTLA-4 and PD-1 or PD-L1 blockade
agents is registered (NCT04335305), in which patients are
randomised to pembrolizumab (a checkpoint inhibitor)
and tocilizumab together versus standard of care.
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Limitations of the study
Our systematic review and meta-analysis has important
limitations. First, the criteria for severe COVID-19 pro
bably select a population that is less acutely ill than the
population of patients with non-COVID-19 ARDS,
because not all patients were admitted to an ICU.
However, many of the patients with severe COVID-19
meet the Berlin criteria for ARDS, all meet clinical criteria
for sepsis, and all exhibit organ dysfunction consistent
with cytokine release syndrome of grade 3 or higher.8,57
Additionally, comparison of critical COVID-19 alone with
the other, non-COVID-19 disorders yielded similar results.
Second, in many instances, biomarker distri
butions
violated many of the assumptions employed by common
biostatistical modelling approaches, making the analyses
complex. However, the differences between COVID-19
and comparator disorders are large enough to be visually
obvious without formal statistical hypothesis testing, and
various sensitivity analyses failed to impugn the stability
of the primary analysis. Nevertheless, our complete
dataset is available in appendix 2 to permit testing of
alternative strategies. Third, our analysis considered only
one IL-6 concentration per study. For COVID-19, we used
the peak IL-6 concentration whenever studies reported
multiple concentrations, whereas for sepsis and ARDS,
we used the enrolment IL-6 concentration, which was
generally recorded less than 24–48 h after presentation.
Therefore, we might have underestimated differences in
cytokine concentrations between these disorders. Even
when comparing only peak IL-6 concentrations in patients
with COVID-19 with those in the other disorders, IL-6
elevations were substantially lower in patients with
COVID-19. Fourth, because tocilizumab is a receptor
antagonist, its administration could have increased the
measured concentrations in some of the studies
examining cytokine release syndrome.13–15 The extent of
treatment-induced IL-6 elevation appears to be disease
variable, with small increases reported in rheu
matoid
arthritis (30 pg/mL) and large increases in Castleman
disease (540 pg/mL) 14 days after admin
istration.71
Tocilizumab probably affects IL-6 concen
tration
measurement in cytokine release syndrome as well.72
However, reactive elevation in IL-6 concentration after
tocilizumab alone is not expected to explain the marked
differences in other cytokine concentrations between
patients with cytokine release syndrome and patients with
COVID-19. Fifth, whereas the studies examining
COVID-19 and cytokine release syndrome are recent,
those examining sepsis and ARDS extend over a longer
time period, and secular changes in cytokine measurement
procedures could have affected the results. Finally,
reporting of cytokines other than IL-6 was variable,
limiting our ability to do all designated secondary analyses.

Conclusions and future directions
Although cytokine concentrations are elevated in
patients with severe and critical COVID-19, the degree
10

of cytokinaemia is markedly less than that seen in other
disorders associated with elevated cytokines. Given
these findings, the descriptor cytokine storm is
problematic and alternative mechanisms of COVID-19induced organ dysfunction are worth considering.
Various ongoing randomised trials will determine
whether cytokine blockade (eg, treatments directed
against IL-6 or IL-1) can improve outcomes in patients
with severe and critical COVID-19. Conversely, immuneactivating treatments (eg, interferons, IL-7, or
checkpoint inhibition) merit investigation, but there are
relatively few registered trials. More broadly, the
immune features of COVID-19 remain largely unsettled.
Deepening patho
biological understanding of severe
SARS-CoV-2 infection and the host response it elicits
must be prioritised. Deploying mechanistic studies
nested within randomised trials offers an important
avenue for basic scientists to explore the biology of
COVID-19 within clinically relevant experimental
systems, while also testing the efficacy and safety of
potential therapeutics. Circulating markers might,
ultimately, help to discriminate diagnoses and generate
hypotheses. However, caution is needed in drawing
inferences about the underlying processes that such
markers reflect and their potential causal roles in
disease. Even as new disease models and therapeutics
gain traction, challenging assumptions is essential and
scepticism is healthy.
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